Orenitram

Report
20 Pages
October 2018
Region: Global
Citeline
ID: 4775236

Drug Overview
Orenitram (treprostinil; United Therapeutics) is a novel formulation of the prostacyclin analog treprostinil, formulated using Supernus Pharmaceuticals’ drug delivery technology, allowing for twice-daily oral dosing. Orenitram represents the continuation of United Therapeutics’ PH portfolio, led by intravenous Remodulin.

Analyst Outlook
Although Orenitram (treprostinil; United Therapeutics) was approved as the first oral prostacyclin analog in the US, addressing an important unmet need of the time, its clinical data are weak and consequently, the drug has only made a minor impact on pulmonary hypertension (PH) market. Moreover, newer brand Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku) poses tough competition in the oral prostacyclin class. To better position its brand, United Therapeutics is investigating Orenitram’s potential in PH associated with left heart disease (PH-LHD) and aiming to use morbidity evidence from the FREEDOM-EV study that could support EU approval. While United Therapeutics is investing in further developing Orenitram, the author ultimately does not foresee Orenitram outcompeting Uptravi as the former’s clinical profile is unconvincing. Nevertheless, Orenitram is still expected to indirectly benefit from the TRITON trial investigating the value of triple combination therapy with an oral prostacyclin

OVERVIEW

Drug Overview
Product Profiles
Orenitram : Pulmonary hypertension

LIST OF FIGURES

Figure 1: Orenitram for pulmonary hypertension – SWOT analysis
Figure 2: The authors drug assessment summary of Orenitram for pulmonary hypertension
Figure 3: Orenitram sales for pulmonary hypertension across the US and five major EU markets, by country, 2016–25

LIST OF TABLES

Table 1: Orenitram drug profile
Table 2: Orenitram pivotal trial data in pulmonary hypertension
Table 3: Orenitram late-phase data in pulmonary hypertension
Table 4: Orenitram ongoing late-phase trials in pulmonary hypertension
Table 5: Orenitram sales for pulmonary hypertension across the US and five major EU markets, by country ($m), 2016–25

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€9652EUR$10,000USD£8,279GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€47295EUR$49,000USD£40,569GBP

Table of Contents

Related Topics

Related Reports

Pulmonary Arterial Hypertension Market Insight, Epidemiology and Market Forecast - 2034

Global Pulmonary Arterial Hypertension Market: Analysis By Drug Class, By Type, By Route of Administration, By Distribution Channel, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2028

Pulmonary Arterial Hypertension Global Market Report 2024

Pulmonary Arterial Hypertension Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Pulmonary Hypertension - Pipeline Insight, 2024